Strategic partnership between Inoviem Scientific and abc biopply in preclinical oncology

On October 8, 2025, ATON SA announced a key partnership between its subsidiary Inoviem Scientific and the Swiss company abc biopply. This partnership aims to develop new solutions in preclinical oncology. Inoviem Scientific, specialized in translational pharmacology, brings its unique access to fresh tumor biopsies and its “Pharmacology on the Spot” technology, preserving the integrity of the tumor microenvironment. For its part, abc biopply uses its 3D multi-organoid™ technology to create miniaturized organ models.

This merger aims to bridge the gap between research and clinical trials by enabling the testing of cancer treatments on human tissue in a 3D environment. This innovation seeks to improve translational predictability and reduce the failure rate in advanced clinical trials. By orchestrating this partnership, Aton confirms its synergistic strategy to accelerate the development of new therapies.